5 top healthcare stocks for earnings growth in 2024

Image of nurse and patient; learn about healthcare stocks

Key Points

  • Analysts forecast healthcare stocks to lead S&P this year in earnings increases.
  • Humana, Elevance, Incyte, Insulet and Cigna are expected to be the biggest earnings gainers.
  • Wall Street says many factors that had been pressuring the industry are largely gone, or already baked into forecasts.
  • 5 stocks we like better than Amgen

While the healthcare sector delivered lackluster profit growth in 2023, it should change this year. 

Sector components forecast to show the biggest earnings year-over-year earnings improvement include Humana Inc. NYSE: HUMElevance Health Inc. NYSE: ELVIncyte Corp. NASDAQ: INCYInsulet Corp. NASDAQ: PODD and Cigna Group NYSE: CI.   

The stock price reflected the tepid 2023 sector performance.

The Health Care Select Sector SPDR Fund NYSEARCA: XLV eked out a 2023 return of 2.06%, primarily due to the strength of a few stocks such as Eli Lilly & Co. NYSE: LLY and Intuitive Surgical Inc. NASDAQ: ISRG

It's outside the S&P 500, but Denmark-based Novo Nordisk A/S NYSE: NVO joins Eli Lilly as a stock that saw significant increases due to anti-obesity medications. Intuitive Surgical was driven primarily by growth in the volume of surgeries using its robotic gear and higher pricing. 

Analysts are forecasting healthcare stocks to post the S&P's biggest earnings increases among all the sectors this year.

Industry pressures easing

In a January 5 report, "What to expect in U.S. healthcare in 2024 and beyond," consulting firm McKinsey said, "The acute strain from labor shortages, inflation, and endemic COVID-19 on the healthcare industry's financial health in 2022 is easing."

However, profit margins are still squeezed, but whenever a company or industry is bouncing back from a series of challenges, there's generally plenty of upside potential. 

Healthcare stocks can sometimes be considered value stocks due to their potential for strong fundamentals, lower valuations relative to fast-growing technology stocks and the market's occasional oversight of healthcare's unique combination of growth potential and stability. 

Sector has growth and defensive traits

Healthcare has elements of both growth and defensives. The former characterization is due to constant research and development and deployment of new technologies, mainly in the biotech area, but also when it comes to infotech and robotics. 

McKinsey analysts addressed that in their 2024 forecast: "On the healthcare delivery side, financial performance will continue to rebound as transformation efforts, M&A, and revenue diversification bear fruit."

They said that adopting new tech will also drive the performance of healthcare services and technology businesses. Specialty pharmacy services should also be a growth area. 

You may consider healthcare stocks defensive, as many of the largest companies in the sector are reliable dividend payers

Earnings outlook for 2024

  • Humana: Wall Street expects the health insurer to grow earnings by 11% this year. Humana analyst forecasts show a consensus view of "moderate buy." 
  • Elevance: Forecasts call for a 12% earnings increase. MarketBeat's Elevance earnings data show a long history of beating earnings views. 
  • Incyte: The developer of cancer treatments should grow earnings by 21% in 2024, with more double-digit growth forecast for 2025.
  • Insulet: Analysts expect a 26% earnings improvement this year, following another solid year in 2023, which the company reports on February 22. 
  • Cigna: The insurance giant should grow earnings by 14% in 2024. Cigna dividend data show the company boosting its shareholder payout for the past three years. 

Why analysts and investors see growth ahead

Analysts believe the widely expected cuts in interest rates would benefit the sector as a whole.

In addition, another worry is largely off the table: Traditionally, healthcare stocks underperform in presidential election years as politicians try to get attention with promises of lower prescription prices or healthcare premiums. 

However, some Washington meddling seems baked into prices.

For example, the Biden administration already pushed through a Medicare drug price negotiation program that's survived legal challenges. Analysts have already incorporated expected changes into their models. 

Finally, while antitrust regulators have become more active in recent years, the approval of Pfizer Inc.'s NYSE: PFE acquisition of Seagen and Amgen Inc.'s NASDAQ: AMGN acquisition of Horizon Therapeutics eased concerns about a possible decline in merger and acquisition deals that spur growth. 

→ The CHIPS Act Motherlode (From True Market Insiders) (Ad)

Should you invest $1,000 in Amgen right now?

Before you consider Amgen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.

While Amgen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Amgen (AMGN)
4.8036 of 5 stars
$312.47-0.7%2.88%44.64Moderate Buy$305.65
Eli Lilly and Company (LLY)
4.8448 of 5 stars
$770.00-0.1%0.68%113.40Moderate Buy$769.53
Health Care Select Sector SPDR Fund (XLV)N/A$146.31+0.2%1.36%23.82N/AN/A
Humana (HUM)
4.9722 of 5 stars
Incyte (INCY)
4.8882 of 5 stars
Insulet (PODD)
4.9355 of 5 stars
$187.27+1.0%N/A56.75Moderate Buy$239.44
Intuitive Surgical (ISRG)
4.6058 of 5 stars
$398.82+0.6%N/A71.99Moderate Buy$396.17
Novo Nordisk A/S (NVO)
2.2646 of 5 stars
$131.89-0.9%1.01%45.48Moderate Buy$133.60
Pfizer (PFE)
4.9975 of 5 stars
Elevance Health (ELV)
3.9103 of 5 stars
$547.71+0.7%1.19%20.70Moderate Buy$587.42
The Cigna Group (CI)
4.8123 of 5 stars
$338.71-0.2%1.65%27.81Moderate Buy$366.14
Compare These Stocks  Add These Stocks to My Watchlist 

Kate Stalter

About Kate Stalter

  • stalterkate@gmail.com

Contributing Author

Retirement, Asset Allocation, and Tax Strategies


Kate Stalter has been a contributing writer for MarketBeat since 2021.

Additional Experience

Series 65-licensed investment advisor, financial advisor, Blue Marlin Advisors; investment columnist for Forbes, U.S. News & World Report

Areas of Expertise

Asset allocation, technical and fundamental analysis, retirement strategies, income generation, risk management, sector and industry analysis


Bachelor of Arts, Saint Mary’s College, Notre Dame, Indiana; Master of Business Adminstration, Kellogg School of Management at Northwestern University

Past Experience

Founder, financial advisor for Better Money Decisions; editor, stock trading instructor for Investor’s Business Daily; columnist, podcast host, video host for MoneyShow.com; contributor for Morningstar magazine

Featured Articles and Offers

5 Hottest CEO Stock Purchases

5 Hottest CEO Stock Purchases

No insider is more significant than the CEO. This is a list of the five most significant CEO purchases in Q1 2024 based on dollar volume.

Search Headlines: